NGM Bio Hosts a Conference Call to Discuss Key Results from the Phase 2 CATALINA Trial of NGM621 in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration



SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) — NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m. ET (5:00 a.m. PT) to discuss key efficacy and safety results from its trial of phase 2 CATALINA of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration.

To access the live webcast and slides, please visit the “Investors and Media” section of NGM Bio’s website at The webcast will be archived for 30 days.

About NGM Bio

NGM Bio is focused on the discovery and development of new, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate the interrogation of complex expertise in disease-associated protein biology and engineering to unlock proprietary insights that are mined to generate products promising candidates and enable their rapid advancement in proof-of-concept studies. As explorers at the frontier of life-changing science, NGM Bio aspires to harness one of the most productive research and development engines in the biopharmaceutical industry. All of the therapeutic candidates in the NGM Bio pipeline have been generated by its internal discovery engine, always driven by biology and driven by unmet patient needs. Today, the company has seven programs in clinical development, four of which are in phase 2 or 2b, including the recently completed NGM621 CATALINA trial, in three therapeutic areas: cancer, retinal diseases and hepatic and metabolic diseases. Visit us at for more information.

main logo

Source link


Comments are closed.